Draft Blueprint for Prescriber Education for Long-Acting/Extended-Release Opioid Class-Wide Risk Evaluation and Mitigation Strategy; Availability; Request for Comments

16 organizations filed 17 public comments on Draft Blueprint for Prescriber Education for Long-Acting/Extended-Release Opioid Class-Wide Risk Evaluation and Mitigation Strategy; Availability; Request for Comments, at the Food and Drug Administration. The comment window closed 5347d ago.

Commenters (16)

• National Association of Medical Education Companiestrade assoc.

  2 filings · confidence 85%
• Accreditation Council for Continuing Medical Educationtrade assoc.

  1 filing · confidence 85%
• Alliance for Continuing Education in the Health Professionstrade assoc.

  1 filing · confidence 85%
• American Academy of Pediatrics (AAP)

  1 filing · confidence 97%
• American Pain Societytrade assoc.

  1 filing · confidence 85%
• American Pharmacists Association (APhA)trade assoc.

  1 filing · confidence 97%
• American Psychiatric Associationtrade assoc.

  1 filing · confidence 85%
• American Society of Addiction Medicinetrade assoc.

  1 filing · confidence 85%
• American Society of Anesthesiologiststrade assoc.

  1 filing · confidence 85%
• American Society of Clinical Oncologytrade assoc.

  1 filing · confidence 85%
• American Society of Health-System Pharmaciststrade assoc.

  1 filing · confidence 85%
• American Society of Interventional Pain Physicianstrade assoc.

  1 filing · confidence 85%
• CME Coalitiontrade assoc.

  1 filing · confidence 85%
• Federation of State Medical Boardstrade assoc.

  1 filing · confidence 85%
• National Community Pharmacists Associationtrade assoc.

  1 filing · confidence 97%
• Quest Diagnostics Incorporatedunverified attribution

  1 filing · confidence 70%